CymaBay Initiates AFFIRM, A Phase 3b/4 Study Evaluating The Effect Of Seladelpar On Clinical Outcomes In Patients With Cirrhosis Due To Primary Biliary Cholangitis
Portfolio Pulse from Benzinga Newsdesk
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has initiated a Phase 3b/4 study, AFFIRM, to evaluate the effect of seladelpar on clinical outcomes in patients with cirrhosis due to primary biliary cholangitis (PBC). The study is designed to fulfill post-marketing requirements of the accelerated approval pathway for seladelpar. The study will enroll approximately 192 patients and will last for three years.
September 21, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CymaBay's initiation of the AFFIRM study could potentially lead to the accelerated approval of seladelpar, which would be a significant milestone for the company.
The initiation of the AFFIRM study is a significant step for CymaBay as it could potentially lead to the accelerated approval of seladelpar. This would be a major milestone for the company and could have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100